Stay updated with breaking news from Target Action Date. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL...
FinancialContent fully hosted finance channel
A panel of advisers to the U.S. Food and Drug Administration voted against approving Intercept Pharmaceuticals' (ICPT) investigational treatment for Nonalcoholic steatohepatitis, a serious progressive liver disease.
Intercept Pharmaceutics, Inc (ICPT) shares are down almost 28% on Monday, after an FDA advisory panel voted against Intercept's drug obeticholic acid for the treatment of nonalcoholic steatohepatitis, or NASH.
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...